연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
575. Surface expression of neutrophil CXCR4 is down-modulated by bacterial endotoxin.
Kim HK, Kim JE, Chung J, Han KS, Cho HI.
Int J Hematol. 2007 Jun;85(5):390-6
Link
574. Lipopolysaccharide down-regulates the thrombomodulin expression of peripheral blood monocytes: effect of serum on thrombomodulin expression in the THP-1 monocytic cell line.
Kim HK, Kim JE, Chung J, Kim YT, Kang SH, Han KS, Cho HI.
Blood Coagul Fibrinolysis. 2007 Mar;18(2):157-64
Link
573. Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy.
Kim HK, Kim JE, Chung J, Lee DS, Han KS, Park S, Cho HI.
Thromb Res. 2007;120(4):559-66. Epub 2007 Jan 18.
Link
572. Utility of the fibrinogen/C-reactive protein ratio for the diagnosis of disseminated intravascular coagulation.
Kim HK, Lee DS, Kang SH, Kim JQ, Park S, Cho HI.
Acta Haematol. 2007;117(1):34-9. Epub 2006 Nov 8
Link
571. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4232-6.
Link
570. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Lee KW, Yun T, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK.
Leuk Lymphoma. 2006 Jul;47(7):1274-82.
Link
569. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ.
Jpn J Clin Oncol. 2006 Jun;36(6):344-50.
Link
568. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ.
Clin Cancer Res. 2006 Apr 15;12(8):2538-44.
Link
567. Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
Park SR, Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS.
J Korean Med Sci. 2006 Aug;21(4):633-8.
Link
566. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ.
Lung Cancer. 2006 Nov;54(2):201-7. Epub 2006 Sep 7.
Link